Abstract
The pharmacokinetics of metronidazole was evaluated in eight patients with alcoholic liver disease. Metronidazole (7.5 mg/kg) was administered to each patient intravenously. Serial blood samples were obtained after the dose. Serum metronidazole concentrations were determined by high-performance liquid chromatography. The following pharmacokinetic parameters (mean +/- standard deviations) were obtained: half-life, 18.31 +/- 6.06 h; elimination rate constant, 0.042 +/- 0.013 h-1; volume of distribution, 0.77 +/- 0.16 liters/kg; and total body clearance, 0.51 +/- 0.11 ml/min per kg. Compared with subjects with normal liver function, patients with liver disease showed a reduction in drug elimination rate and total body clearance. The half-life of metronizadole in serum and volume of distribution were increased. Large variations of these parameters were also observed among the patients. On the basis of these observations, a reduced dose of metronidazole should be given to patients with alcoholic liver disease to avoid accumulation of metronidazole and its metabolites. Monitoring of drug concentration in serum may also be necessary to optimize therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Daneshmend T. K., Homeida M., Kaye C. M., Elamin A. A., Roberts C. J. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut. 1982 Oct;23(10):807–813. doi: 10.1136/gut.23.10.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Finegold S. M. Metronidazole. Ann Intern Med. 1980 Oct;93(4):585–587. doi: 10.7326/0003-4819-93-4-585. [DOI] [PubMed] [Google Scholar]
- Jensen J. C., Gugler R. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther. 1983 Oct;34(4):481–487. doi: 10.1038/clpt.1983.201. [DOI] [PubMed] [Google Scholar]
- Lau A. Pharmacokinetics of metronidazole in hospitalized patients. Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):643–645. [PubMed] [Google Scholar]
- Ralph E. D. Clinical pharmacokinetics of metronidazole. Clin Pharmacokinet. 1983 Jan-Feb;8(1):43–62. doi: 10.2165/00003088-198308010-00003. [DOI] [PubMed] [Google Scholar]
- Schentag J. J., Ziemniak J. A., Greco J. M., Rainstein M., Buckley R. J. Mental confusion in a patient treated with metronidazole--a concentration-related effect? Pharmacotherapy. 1982 Nov-Dec;2(6):384–387. doi: 10.1002/j.1875-9114.1982.tb03216.x. [DOI] [PubMed] [Google Scholar]
- Stambaugh J. E., Feo L. G., Manthei R. W. The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther. 1968 Jun;161(2):373–381. [PubMed] [Google Scholar]
- Tally F. P., Sullivan C. E. Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections. Pharmacotherapy. 1981 Jul-Aug;1(1):28–38. doi: 10.1002/j.1875-9114.1981.tb03551.x. [DOI] [PubMed] [Google Scholar]
- Wheeler L. A., De Meo M., Halula M., George L., Heseltine P. Use of high-pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration. Antimicrob Agents Chemother. 1978 Feb;13(2):205–209. doi: 10.1128/aac.13.2.205. [DOI] [PMC free article] [PubMed] [Google Scholar]